JBCPL shareholders approve pharma portfolio sale to Dr Reddys

Shareholders of JBCPL authorised the sale of Russia-CIS prescription products to Dr Reddy.

Shareholders of JB Chemicals and Pharmaceuticals Ltd (JBCPL)have approved the board’s decision to sell pharmaceutical prescription portfolio of the company in Russia and other CIS regions to Dr Reddys Laboratories,the company said today.

“The shareholders of the company have passed a resolution with requisite majority authorising the sale of Russia-CIS prescription products to Dr Reddys laboratories,” JB Chemicals said in a filing with the Bombay Stock Exchange.

Dr Reddys Lab in July had announced that it has entered into an agreement with Mumbai-based JB Chemicals to acquire its pharmaceutical prescription portfolio in Russia and other CIS regions for USD 20 million.

Story continues below this ad

The agreement involves acquisition of 20 brands,key ones being Metrogyl and Jocet. Dr Reddys has also entered into a supply agreement with JB Chemicals for continued manufacturing and supply of these products associated with the acquired brands.

Russia is one of the leading markets for DRL and this acquisition will help expand the prescription,hospital and OTC portfolio of the company there,DRL had earlier said.

JB Chemicals had recently completed a Rs 939 crore deal to sell its over-the-counter business in Russia and CIS countries to Johnson & Johnson arm Cilag GmbH International.